Loading viewer...
investor_presentation
Format: PDF investor_presentation
Cipla's Q2 FY2023 investor presentation highlights strong revenue growth of 6% YoY (12% ex-covid) driven by One-India momentum and differentiated North America portfolio including Lenalidomide launch. The company achieved overall revenue of INR 5,829 Cr with adjusted EBITDA margin of 22.3% and maintained robust traction across core therapeutic areas and business segments.
investor_presentation
19 Pages
investor_presentation
20 Pages
U.S. Bancorp
investor_presentation
Ocean Yield